Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 5/2016

01-05-2016 | Original Research

Effect of Concurrent Use of Whole-Body Vibration and Parathyroid Hormone on Bone Structure and Material Properties of Ovariectomized Mice

Authors: Takeshi Matsumoto, Shinya Itamochi, Yoshihiro Hashimoto

Published in: Calcified Tissue International | Issue 5/2016

Login to get access

Abstract

This study was designed to determine the effectiveness of whole-body vibration (WBV) and intermittent parathyroid hormone (iPTH) in combination against estrogen deficiency-induced osteoporosis. Female C57BL/6J mice were bilaterally ovariectomized (OVX, n = 40) or sham-operated (sham-OVX, n = 8) at 9 weeks of age. Two weeks later, the OVX mice were randomly divided into four groups (n = 10 each): the control group (c-OVX) and groups treated with iPTH (p-OVX), WBV (w-OVX) and both (pw-OVX). The p-OVX and pw-OVX groups were given human PTH (1–34) at a dose of 30 µg/kg/day. The w-OVX and pw-OVX groups were exposed to WBV at an acceleration of 0.3 g and 45 Hz for 20 min/day. All mice were euthanized after the 18-day treatment, and the left tibiae were harvested. The proximal metaphyseal region was µCT-scanned, and its cortical bone cross-section was analyzed by Fourier transform infrared microspectroscopy and nanoindentation testing. A single application of iPTH or WBV to OVX mice had no effect on bone structure or material properties of cortical bone, which were compromised in comparison to those in sham-OVX mice. The combination of iPTH and WBV improved trabecular bone volume, thickness, and connectivity in OVX mice. Although the combined treatment failed to improve cortical bone structure, its mineral maturity and hardness were restored to the levels observed in sham-OVX mice. There was no evidence of interaction between the two treatments, and the combined effects seemed to be additive. These results suggest combining WBV with iPTH has great potential for treating postmenopausal osteoporosis.
Literature
1.
Peck WA et al (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650CrossRef
2.
Lane NE (2006) Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 194:S3–S11CrossRefPubMed
3.
Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, Ishibashi H, Kawaguchi H, Nakamura K, Akune T (2009) Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27:620–628CrossRefPubMed
4.
Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T (2010) Cohort profile: research on Osteoarthritis/Osteoporosis Against Disability study. Int J Epidemiol 39:988–995CrossRefPubMed
5.
Ravn P, Rix M, Andreassen H, Clemmesen B, Bidstrup M, Gunnes M (1997) High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women. Calcif Tissue Int 60:255–260CrossRefPubMed
6.
D’Amelio P, Grimaldi A, Di Bella S, Brianza SZ, Cristofaro MA, Tamone C, Giribaldi G, Ulliers D, Pescarmona GP, Isaia G (2008) Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone 43:92–100CrossRefPubMed
7.
Gaudio A, Morabito N (2005) Pharmacological management of severe postmenopausal osteoporosis. Drugs Aging 22:405–417CrossRefPubMed
8.
Papapoulos S, Makras P (2008) Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 4:514–523CrossRefPubMed
9.
Gallacher SJ, Dixon T (2010) Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int 87:469–484CrossRefPubMed
10.
Qin L, Raggatt LJ, Partridge NC (2004) Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 15:60–65CrossRefPubMed
11.
12.
Fox J, Miller MA, Recker RR, Bare SP, Smith SY, Moreau I (2005) Treatment of postmenopausal osteoporotic women with parathyroid hormone 1–84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 5:356–357PubMed
13.
Senn C, Günther B, Popp AW, Perrelet R, Hans D, Lippuner K (2014) Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int 25:1945–1951CrossRefPubMed
14.
Alexander JM, Bab I, Fish S, Müller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M, Gazit D, Rosenblatt M (2001) Human parathyroid hormone 1–34 reverses bone loss in ovariectomized mice. J Bone Miner Res 16:1665–1673CrossRefPubMed
15.
Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY (2006) Daily treatment of aged ovariectomized rats with human parathyroid hormone (1–84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 79:262–272CrossRefPubMed
16.
17.
Aguirre JI, Plotkin LI, Gortazar AR, Millan MM, O’Brien CA, Manolagas SC, Bellido T (2007) A novel ligand-independent function of the estrogen receptor is essential for osteocyte and osteoblast mechanotransduction. J Biol Chem 282:25501–25508CrossRefPubMed
18.
Wehrle E, Liedert A, Heilmann A, Wehner T, Bindl R, Fischer L, Haffner-Luntzer M, Jakob F, Schinke T, Amling M, Ignatius A (2015) The impact of low-magnitude high-frequency vibration on fracture healing is profoundly influenced by the oestrogen status in mice. Dis Model Mech 8:93–104CrossRefPubMedPubMedCentral
19.
Prisby RD, Lafage-Proust MH, Malaval L, Belli A, Vico L (2008) Effects of whole body vibration on the skeleton and other organ systems in man and animal models: what we know and what we need to know. Ageing Res Rev 7:319–329CrossRefPubMed
20.
Slatkovska L, Alibhai SM, Beyene J, Cheung AM (2010) Effect of whole-body vibration on BMD: a systematic review and meta-analysis. Osteoporos Int 21:1969–1980CrossRefPubMed
21.
Rubinacci A, Marenzana M, Cavani F, Colasante F, Villa I, Willnecker J, Moro GL, Spreafico LP, Ferretti M, Guidobono F, Marotti G (2008) Ovariectomy sensitizes rat cortical bone to whole-body vibration. Calcif Tissue Int 82:316–326CrossRefPubMed
22.
Oxlund BS, Ørtoft G, Andreassen TT, Oxlund H (2003) Low-intensity, high-frequency vibration appears to prevent the decrease in strength of the femur and tibia associated with ovariectomy of adult rats. Bone 32:69–77CrossRefPubMed
23.
Zhou Y, Guan X, Liu T, Wang X, Yu M, Yang G, Wang H (2015) Whole body vibration improves osseointegration by up-regulating osteoblastic activity but down-regulating osteoblast-mediated osteoclastogenesis via ERK1/2 pathway. Bone 71:17–24CrossRefPubMed
24.
Rubin C, Recker R, Cullen D, Ryaby J, McCabe J, McLeod K (2004) Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: a clinical trial assessing compliance, efficacy, and safety. J Bone Miner Res 19:343–351CrossRefPubMed
25.
Kiel DP, Hannan MT, Barton BA, Bouxsein ML, Sisson E, Lang T, Allaire B, Dewkett D, Carroll D, Magaziner J, Shane E, Leary ET, Zimmerman S, Rubin CT (2015) Low-magnitude mechanical stimulation to improve bone density in persons of advanced age: a randomized, placebo-controlled trial. J Bone Miner Res 30:1319–1328CrossRefPubMed
26.
Chow JW, Fox S, Jagger CJ, Chambers TJ (1998) Role for parathyroid hormone in mechanical responsiveness of rat bone. Am J Physiol 274:E146–E154PubMed
27.
Hagino H, Okano T, Akhter MP, Enokida M, Teshima R (2001) Effect of parathyroid hormone on cortical bone response to in vivo external loading of the rat tibia. J Bone Miner Metab 19:244–250CrossRefPubMed
28.
Kim CH, Takai E, Zhou H, von Stechow D, Müller R, Dempster DW, Guo XE (2003) Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. J Bone Miner Res 18:2116–2125CrossRefPubMed
29.
Roberts MD, Santner TJ, Hart RT (2009) Local bone formation due to combined mechanical loading and intermittent hPTH-(1-34) treatment and its correlation to mechanical signal distributions. J Biomech 42:2431–2438CrossRefPubMed
30.
McAteer ME, Niziolek PJ, Ellis SN, Alge DL, Robling AG (2010) Mechanical stimulation and intermittent parathyroid hormone treatment induce disproportional osteogenic, geometric, and biomechanical effects in growing mouse bone. Calcif Tissue Int 86:389–396CrossRefPubMedPubMedCentral
31.
Warden SJ, Komatsu DE, Rydberg J, Bond JL, Hassett SM (2009) Recombinant human parathyroid hormone (PTH 1-34) and low-intensity pulsed ultrasound have contrasting additive effects during fracture healing. Bone 44:485–494CrossRefPubMed
32.
Otsu N (1979) Threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern 9:62–66CrossRef
33.
Hildebrand T, Ruegsegger P (1997) A new method for the model-independent assessment of thickness in three-dimensional images. J Microsc 185:67–75CrossRef
34.
Doube M, Kłosowski MM, Arganda-Carreras I, Cordelières FP, Dougherty RP, Jackson JS, Schmid B, Hutchinson JR, Shefelbine SJ (2010) BoneJ: free and extensible bone image analysis in ImageJ. Bone 47:1076–1079CrossRefPubMedPubMedCentral
35.
Hengsberger S, Kulik A, Zysset P (2002) Nanoindentation discriminates the elastic properties of individual human bone lamellae under dry and physiological conditions. Bone 30:178–184CrossRefPubMed
36.
Dong A, Huang P, Caughey WS (1990) Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry 29:3303–3308CrossRefPubMed
37.
Gadaleta SJ, Paschalis EP, Betts F, Mendelsohn R, Boskey AL (1996) Fourier transform infrared spectroscopy of the solution-mediated conversion of amorphous calcium phosphate to hydroxyapatite: new correlations between X-ray diffraction and infrared data. Calcif Tissue Int 58:9–16CrossRefPubMed
38.
Silva MJ, Brodt MD, Fan Z, Rho JY (2004) Nanoindentation and whole-bone bending estimates of material properties in bones from the senescence accelerated mouse SAMP6. J Biomech 37:1639–1646CrossRefPubMed
39.
Oliver W, Pharr G (2004) Measurement of hardness and elastic modulus by instrumented indentation: advances in understanding and refinements to methodology. J Mater Res 19:3–20CrossRef
40.
Andersson N, Lindberg MK, Ohlsson C, Andersson K, Ryberg B (2001) Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice. J Endocrinol 170:529–537CrossRefPubMed
41.
Zhou H, Iida-Klein A, Lu SS, Ducayen-Knowles M, Levine LR, Dempster DW, Lindsay R (2003) Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32:513–520CrossRefPubMed
42.
Xiang A, Kanematsu M, Mitamura M, Kikkawa H, Asano S, Kinoshita M (2006) Analysis of change patterns of microcomputed tomography 3-dimensional bone parameters as a high-throughput tool to evaluate antiosteoporotic effects of agents at an early stage of ovariectomy-induced osteoporosis in mice. Invest Radiol 41:704–712CrossRefPubMed
43.
Rogers NH, Perfield JW, Strissel KJ, Obin MS, Greenberg AS (2009) Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology 150:2161–2168CrossRefPubMedPubMedCentral
44.
Farlay D, Bala Y, Bare S, Lappe J, Recker R, Boivin G (2012) Modifications of bone material properties early detected after 1 year of menopause in women. J Bone Miner Res 27:FR 0144
45.
Wen XX, Wang FQ, Xu C, Wu ZX, Zhang Y, Feng YF, Yan YB, Lei W (2015) Time related changes of mineral and collagen and their roles in cortical bone mechanics of ovariectomized rabbits. PLoS ONE 10:e0127973CrossRefPubMedPubMedCentral
46.
Zhang Y, Lai WP, Leung PC, Wu CF, Wong MS (2007) Short- to mid-term effects of ovariectomy on bone turnover, bone mass and bone strength in rats. Biol Pharm Bull 30:898–903CrossRefPubMed
47.
Brennan O, Kuliwaba JS, Lee TC, Parkinson IH, Fazzalari NL, McNamara LM, O’Brien FJ (2012) Temporal changes in bone composition, architecture, and strength following estrogen deficiency in osteoporosis. Calcif Tissue Int 91:440–449CrossRefPubMed
48.
Mathavan N, Turunen MJ, Tägil M, Isaksson H (2015) Characterising bone material composition and structure in the ovariectomized (OVX) rat model of osteoporosis. Calcif Tissue Int 97:134–144CrossRefPubMed
49.
Pierroz DD, Bouxsein ML, Rizzoli R, Ferrari SL (2006) Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone 39:260–267CrossRefPubMed
50.
Yamane H, Sakai A, Mori T, Tanaka S, Moridera K, Nakamura T (2009) The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. Bone 44:1055–1062CrossRefPubMed
51.
Roche B, Vanden-Bossche A, Malaval L, Normand M, Jannot M, Chaux R, Vico L, Lafage-Proust MH (2014) Parathyroid hormone 1–84 targets bone vascular structure and perfusion in mice: impacts of its administration regimen and of ovariectomy. J Bone Miner Res 29:1608–1618CrossRefPubMed
52.
Masiukiewicz US, Mitnick M, Grey AB, Insogna KL (2000) Estrogen modulates parathyroid hormone-induced interleukin-6 production in vivo and in vitro. Endocrinology 141:2526–2531PubMed
53.
Xie L, Jacobson JM, Choi ES, Busa B, Donahue LR, Miller LM, Rubin CT, Judex S (2006) Low-level mechanical vibrations can influence bone resorption and bone formation in the growing skeleton. Bone 39:1059–1066CrossRefPubMed
54.
Xie L, Rubin C, Judex S (2008) Enhancement of the adolescent murine musculoskeletal system using low-level mechanical vibrations. J Appl Physiol 104:1056–1062CrossRefPubMed
55.
Chen GX, Zheng S, Qin S, Zhong ZM, Wu XH, Huang ZP, Li W, Ding RT, Yu H, Chen JT (2014) Effect of low-magnitude whole-body vibration combined with alendronate in ovariectomized rats: a random controlled osteoporosis prevention study. PLoS ONE 9:e96181CrossRefPubMedPubMedCentral
56.
Lynch MA, Brodt MD, Stephens AL, Civitelli R, Silva MJ (2011) Low-magnitude whole-body vibration does not enhance the anabolic skeletal effects of intermittent PTH in adult mice. J Orthop Res 29:465–472CrossRefPubMedPubMedCentral
57.
Judex S, Lei X, Han D, Rubin C (2007) Low-magnitude mechanical signals that stimulate bone formation in the ovariectomized rat are dependent on the applied frequency but not on the strain magnitude. J Biomech 40:1333–1339CrossRefPubMed
58.
Lynch MA, Brodt MD, Silva MJ (2010) Skeletal effects of whole-body vibration in adult and aged mice. J Orthop Res 28:241–247PubMedPubMedCentral
59.
Klinck J, Boyd SK (2008) The magnitude and rate of bone loss in ovariectomized mice differs among inbred strains as determined by longitudinal in vivo micro-computed tomography. Calcif Tissue Int 83:70–79CrossRefPubMed
60.
Parfitt AM (1983) The physiologic and clinical significance of bone histomorphometric data. In: Recker R (ed) Bone histomorphometry. techniques and interpretations. CRC Press, Boca Raton, pp 143–223
61.
O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T (2008) Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 3:e2942CrossRefPubMedPubMedCentral
62.
63.
Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577–4583CrossRefPubMed
64.
65.
Turner S, Torode M, Climstein M, Naughton G, Greene D, Baker MK, Fiatarone Singh MA (2011) A randomized controlled trial of whole body vibration exposure on markers of bone turnover in postmenopausal women. J Osteoporos 2011:710387CrossRefPubMedPubMedCentral
66.
Wei QS, Wang HB, Wang JL, Fang B, Zhou GQ, Tan X, He W, Deng WM (2015) Combination treatment with whole body vibration and a kidney-tonifying herbal Fufang prevent osteoporosis in ovariectomized rats. Orthop Surg 7:57–65CrossRefPubMed
67.
Farlay D, Panczer G, Rey C, Delmas PD, Boivin G (2010) Mineral maturity and crystallinity index are distinct characteristics of bone mineral. J Bone Miner Metab 28:433–445CrossRefPubMedPubMedCentral
68.
Bala Y, Farlay D, Boivin G (2013) Bone mineralization: from tissue to crystal in normal and pathological contexts. Osteoporos Int 24:2153–2166CrossRefPubMed
69.
Christiansen BA, Silva MJ (2006) The effect of varying magnitudes of whole-body vibration on several skeletal sites in mice. Ann Biomed Eng 34:1149–1156CrossRefPubMed
Metadata
Title
Effect of Concurrent Use of Whole-Body Vibration and Parathyroid Hormone on Bone Structure and Material Properties of Ovariectomized Mice
Authors
Takeshi Matsumoto
Shinya Itamochi
Yoshihiro Hashimoto
Publication date
01-05-2016
Publisher
Springer US
Published in
Calcified Tissue International / Issue 5/2016
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-015-0104-4

Other articles of this Issue 5/2016

Calcified Tissue International 5/2016 Go to the issue

Original Research

Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis

Original Research

Bone Mineral Density and Cognitive Decline in Elderly Women: Results from the InCHIANTI Study

Original Research

The Implications of the Sequestosome 1 Mutation P392L in Patients with Paget’s Disease in a United States Cohort

Review

A Systematic Review of the Role of Vitamin D on Neuromuscular Remodelling Following Exercise and Injury

Original Research

Bone Microarchitecture in Men and Women with Diabetes: The Importance of Cortical Porosity

Original Research

Palmitic Acid Reduces Circulating Bone Formation Markers in Obese Animals and Impairs Osteoblast Activity via C16-Ceramide Accumulation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits